Drug intelligence / Profile preview

bifidobacterium animalis subsp. lactis HN019 + lactobacillus rhamnosus HN001 + bifidobacterium animalis subsp. lactis Bb-12 + lactobacillus acidophilus NCFM + bifidobacterium breve M-16V

Development stage: Unknown
Lead developer: International Flavors & Fragrances
Modality: Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Oral

Overview

This multi-strain probiotic formulation combines five well-characterized and clinically documented bacterial strains: *Bifidobacterium animalis* subsp. *lactis* HN019, *Lactobacillus rhamnosus* HN001, *Bifidobacterium animalis* subsp. *lactis* Bb-12, *Lactobacillus acidophilus* NCFM, and *Bifidobacterium breve* M-16V. These strains are sourced from leading microbial developers including IFF (formerly Danisco), Chr. Hansen, and Morinaga Milk Industry. The combination is designed to support gastrointestinal health and immune function through synergistic mechanisms such as the modulation of gut microbiota composition, enhancement of the intestinal epithelial barrier, and regulation of systemic immune responses via Toll-like receptor signaling. Clinical studies on the individual strains have demonstrated benefits in reducing gut transit time, alleviating symptoms of irritable bowel syndrome (IBS), preventing atopic dermatitis in infants, and supporting respiratory health. This specific blend is commonly utilized in premium dietary supplements and health foods, particularly in the Asia-Pacific market under brands like Life-Space.

Brand names: Life-SpaceBy-Health
Other names: HOWARU BifidoHOWARU RhamnosusHOWARU AcidophilusBifidobacterium lactis Bb-12Bifidobacterium breve M-16V动物双歧杆菌乳亚种HN019 + 鼠李糖乳酪杆菌HN001 + 动物双歧杆菌乳亚种Bb-12 + 嗜酸乳杆菌NCFM + 短双歧杆菌M-16V

Targets

TLR2 (Toll-like Receptor 2)

Beyond the preview

Go deeper on bifidobacterium animalis subsp. lactis HN019 + lactobacillus rhamnosus HN001 + bifidobacterium animalis subsp. lactis Bb-12 + lactobacillus acidophilus NCFM + bifidobacterium breve M-16V.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on bifidobacterium animalis subsp. lactis HN019 + lactobacillus rhamnosus HN001 + bifidobacterium animalis subsp. lactis Bb-12 + lactobacillus acidophilus NCFM + bifidobacterium breve M-16V.

Explore the full profile